Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2001 1
2002 3
2003 2
2004 1
2005 2
2006 3
2007 2
2008 2
2009 1
2010 5
2011 8
2012 6
2013 2
2014 6
2015 8
2016 8
2017 7
2018 7
2019 11
2020 11
2021 6
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "BRCA-Associated Malignant Neoplasm"
Page 1
Tumour lineage shapes BRCA-mediated phenotypes.
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Jonsson P, et al. Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10. Nature. 2019. PMID: 31292550 Free PMC article.
Here we show that in the 2.7% and 1.8% of patients with advanced-stage cancer and germline pathogenic or somatic loss-of-function alterations in BRCA1/2, respectively, selective pressure for biallelic inactivation, zygosity-dependent phenotype penetrance, and sensitivity to PARP …
Here we show that in the 2.7% and 1.8% of patients with advanced-stage cancer and germline pathogenic or somatic loss-of-function alteration …
Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA. Bellcross CA. Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005. Obstet Gynecol Clin North Am. 2022. PMID: 35168766 Review.
While many new genes have been identified and are included in testing panels, HBOC will serve as the primary example to illustrate the main concepts involved in genetic testing and management for hereditary breast and/or ovarian cancer We provide practical information regarding c …
While many new genes have been identified and are included in testing panels, HBOC will serve as the primary example to illustrate the main …
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, Peer E, Denroche RE, Zhang A, Notta F, Wilson JM, O'Kane GM, Haimov Talmoud E, Amison N, Schvimer M, Salpeter SJ, Bar V, Zundelevich A, Tirosh I, Tal R, Dinstag G, Kinar Y, Eliezer Y, Ben-David U, Gavert NS, Straussman R, Gallinger SJ, Berger R, Golan T. Stossel C, et al. Cancer Discov. 2023 Aug 4;13(8):1826-1843. doi: 10.1158/2159-8290.CD-22-0412. Cancer Discov. 2023. PMID: 37449843 Free PMC article.
Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. ...This work demonstrates the utility of preclinical models, including EVOC, to predict the response of glBRCA PDAC to treatment, w …
Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition …
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A, Scambia G, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31. Cancer Treat Rev. 2023. PMID: 37939446 Free article. Review.
Today, the deeper knowledge on the significant relationship among all proteins involved in the HRR, not limited to BRCA, expands the possibility of a successful non-BRCA, HRD-PARPi synthetic lethality and, at the same time, reinforces the need for enhanced definition of HRD bioma …
Today, the deeper knowledge on the significant relationship among all proteins involved in the HRR, not limited to BRCA, expands the possibi …
BRCA1/2 reversion mutations in a pan-cancer cohort.
Nakamura K, Hayashi H, Kawano R, Ishikawa M, Aimono E, Mizuno T, Kuroda H, Kojima Y, Niikura N, Kawanishi A, Takeshita K, Suzuki S, Ueno S, Okuwaki K, Sasaki J, Yamaguchi M, Masuda K, Chiyoda T, Yamagami W, Okada C, Nohara S, Tanishima S, Nishihara H. Nakamura K, et al. Cancer Sci. 2024 Feb;115(2):635-647. doi: 10.1111/cas.16033. Epub 2023 Dec 1. Cancer Sci. 2024. PMID: 38041241 Free PMC article.
Tumor sensitivity to platinum (Pt)-based chemotherapy and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors is increased by homologous recombination deficiency-causing mutations; in particular, reversion mutations cause drug resistance by restoring protein function. …
Tumor sensitivity to platinum (Pt)-based chemotherapy and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors is increased by ho …
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R. Golan T, et al. Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23. Int J Cancer. 2018. PMID: 29396858 Free article.
The sensitivity to DNA-damaging agents was evaluated in vivo in three BRCA-associated PDAC PDXs models: (1) HRD-genome naive to treatments; (2) stable-genome naive to treatment; (3) HRD-genome resistant to treatment. ...Our results demonstrate heterogeneous response …
The sensitivity to DNA-damaging agents was evaluated in vivo in three BRCA-associated PDAC PDXs models: (1) HRD-genome naive t …
Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Pallonen TA, et al. Sci Rep. 2022 Apr 25;12(1):6704. doi: 10.1038/s41598-022-10519-y. Sci Rep. 2022. PMID: 35469032 Free PMC article.

The risk ratio for bilateral breast cancer is approximately four times when compared BRCA2 (17%) and other counselled patients' group (4%) (p < 0.05). 27% southwestern BRCA2-families have a unique PV, and correspondingly 39% of BRCA1-families. The results of this analysis allo

…
The risk ratio for bilateral breast cancer is approximately four times when compared BRCA2 (17%) and other counselled patients' group (4%) ( …
Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.
Shapiro GI, Barry SM. Shapiro GI, et al. Cancer Treat Res. 2023;186:207-221. doi: 10.1007/978-3-031-30065-3_12. Cancer Treat Res. 2023. PMID: 37978138
While the activity of these agents is largely linked to multiple mechanisms underlying the synthetic lethality of PARP inhibition and HR deficiency, emerging data suggest that their efficacy is also tied to their effects on the immune microenvironment and dependent upon cytotoxic …
While the activity of these agents is largely linked to multiple mechanisms underlying the synthetic lethality of PARP inhibition and HR def …
Clinical outcomes and Oncotype DX Breast Recurrence Score in early-stage BRCA-associated hormone receptor-positive breast cancer.
Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Layman RM, et al. Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6. Cancer Med. 2022. PMID: 35128817 Free PMC article.
Patients with BRCA mutations were younger and received more adjuvant chemotherapy, but less endocrine therapy and radiation therapy. BRCA-associated breast cancers had less progesterone receptor expression, higher nuclear grade, and higher Oncotype DX Breast Recurre …
Patients with BRCA mutations were younger and received more adjuvant chemotherapy, but less endocrine therapy and radiation therapy. BRCA …
BRCA-associated pancreatic cancer: the evolving management.
Leung K, Saif MW. Leung K, et al. JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462. JOP. 2013. PMID: 23474559 Free article. Review.
Pancreatic cancer is one of the deadliest cancers. While BRCA-associated pancreatic cancers are uncommon, the distinctive phenotype of this malignancy may offer unique therapeutic targets. ...We will review these abstracts and our current knowledge of the treatment …
Pancreatic cancer is one of the deadliest cancers. While BRCA-associated pancreatic cancers are uncommon, the distinctive phen …
103 results